<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>Journal of Medical Hypotheses and Ideas</JournalTitle><Volume>2</Volume><Issue></Issue></Journal><ArticleTitle>Anti- vascular endothelial growth factor (Anti-VEGF) as a potential novel adjunct in the management of choroidal melanoma</ArticleTitle><FirstPage>13</FirstPage><LastPage>14</LastPage><AuthorList><Author><FirstName></FirstName><LastName>Mohammad Hosein Nowroozzadeh</LastName></Author><Author><FirstName></FirstName><LastName>Mohammad Sharifi</LastName></Author></AuthorList><History><PubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>05</Day></PubDate></History><Abstract>Tumor microvascularity is a significant determinant of prognosis for a large number of different tumors, including choroidal melanoma. The development of blood vessels within these and other tumors is partly controlled by soluble pro-angiogenic cytokines, of which basic fibroblast growth factor (BFGF) and vascular endothelial growth factor-A (VEGF-A) are the best described. The vitreo-retinal service in the recent years enjoyed a high level of success in managing choroidal neovascularization using anti-VEGF strategies. Efficacy and tolerability have been demonstrated for drugs targeting VEGF-A. In this article, we briefly review the evidences supporting involvement of VEGF-A in the pathogenesis of choroidal melanoma and then based on these evidences, we hypothesize the local application of anti-VEGF agents may stop the progression or prevent the metastasis from choroidal melanoma.</Abstract><web_url>https://ijmhi.tums.ac.ir/index.php/ijmhi/article/view/29</web_url><pdf_url>https://ijmhi.tums.ac.ir/index.php/ijmhi/article/download/29/29</pdf_url></Article></Articles>
